ALK translocations represented by EML4-ALK fusion are found to be mutually exclusive with EGFR or K-Ras mutations and predict for primary resistance to EGFR TKIs in patients with advanced NSCLC since EGFR output is not key to cell survival in these tumors [71]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.